# Lipid nanoparticles show promise in shrinking resistant oral tumors Novel dual-action treatment demonstrates efficacy in preclinical models - **Source:** [Phys.org - latest science and technology news stories](https://brifing.si/source/8b0f98da-d179-4c93-871f-7ac460bf9c61) - **Published:** 2026-07-23 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/9ddfaf83-9d07-4db9-a028-c1b6e2c5ca03 ## Treatment challenges in oral cancer Oral squamous cell carcinoma is the most prevalent head and neck cancer, with cases expected to rise 30% in the next decade. Current surgical and radiation treatments often cause permanent damage to essential functions like speech and swallowing. ## Low survival rates persist This aggressive cancer has a five-year survival rate of only about 50%. Treatment-resistant tumors and therapy side effects create significant quality-of-life issues for patients. ## Nanotechnology breakthrough Researchers developed a targeted drug delivery system using lipid nanoparticles. This approach delivers medications directly to cancer cells while minimizing harm to healthy tissues. ## Dual-action therapeutic mechanism The new system simultaneously delivers tumor-targeting drugs and stimulates the immune system. This two-pronged approach shows effectiveness even against treatment-resistant tumors. ## Promising preclinical results Animal studies demonstrated significant tumor shrinkage with the lipid nanoparticle treatment. The therapy proved effective against cancers resistant to standard treatments. ## Path to clinical trials These findings could herald a new era in oral cancer treatment. However, human clinical trials are needed to confirm safety and efficacy. Success could improve quality of life for thousands of patients worldwide. ## Sources covering this story - https://phys.org/news/2026-07-lipid-nanoparticles-resistant-oral-tumors.html — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._